thelancet.com
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
BI 764198 lowered proteinuria and was well tolerated by participants in this trial.
This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger
randomised controlled trials...